제품 수집
제품 세부정보
Synonym
PVR, FLJ25946, PVS, CD155, TAGE4, HVED, NECL5
Source
Human CD155, Mouse IgG2a Fc Tag (CD5-H5254) is expressed from human 293 cells (HEK293). It contains AA Trp 21 - Asn 343 (Accession # NP_006496.4).
Predicted N-terminus: Trp 21
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 62.2 kDa. The protein migrates as 70-100 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
SDS-PAGE
Human CD155, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA
Immobilized Human TIGIT, Fc Tag (Cat. No. TIT-H5254) at 2 μg/mL (100 μL/well) can bind Human CD155, Mouse IgG2a Fc Tag (Cat. No. CD5-H5254) with a linear range of 0.3-2 ng/mL (QC tested).
Protocol
Immobilized Human DNAM-1, Fc Tag (Cat. No. DN1-H5257) at 2 μg/mL (100 μL/well) can bind Human CD155, Mouse IgG2a Fc Tag (Cat. No. CD5-H5254) with a linear range of 1-16 ng/mL (Routinely tested).
Protocol
Serial dilutions of Human TIGIT Neutralizing antibody were added into Human CD155, Mouse IgG2a Fc Tag (Cat. No. CD5-H5254): Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) binding reactions. The half maximal inhibitory concentration (IC50) is 0.08116 μg/mL (Routinely tested).
Protocol
Bioactivity-BLI
Loaded Human CD155, Mouse IgG2a Fc Tag (Cat. No. CD5-H5254) on Protein A Biosensor, can bind Human TIGIT, His Tag with an affinity constant of 0.24 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Human CD155, Mouse IgG2a Fc Tag (Cat. No. CD5-H5254) on Protein A Biosensor, can bind Human DNAM-1, His Tag (Cat. No. DN1-H52H6) with an affinity constant of 0.57 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Bioactivity-FACS
FACS assay shows that Human CD155, Mouse IgG2a Fc Tag (Cat. No. CD5-H5254) can bind to 293T cell overexpressing human TIGIT. The concentration of CD155 is 1 μg/mL (Routinely tested).
Protocol
FACS analysis shows that the binding of Human CD155, Mouse IgG2a Fc Tag (Cat. No. CD5-H5254) to 293T overexpressing TIGIT was inhibited by increasing concentration of neutralizing Anti-Human TIGIT MAb. The concentration of CD155 used is 1 μg/mL. The IC50 is 0.1413 μg/mL (Routinely tested).
Protocol
사용자 리뷰 댓글 남기기
배경 소개
CD155/PVR was originally isolated based on its ability to mediate polio virus attachment to host cells. The fulllength (or CD155 alpha isoform) is synthesized as a 417 amino acid (aa) precursor that contains a 20 aa signal sequence, a 323 aa extracellular region, a 24 aa TM segment and a 50 aa cytoplasmic tail. The extracellular region contains one N terminal V type and two C2 type Ig like domains.
CD155 is a transmembrane protein with 3 extracellular immunoglobulin-like domains, D1-D3, where D1 is recognized by the virus. Low resolution structures of CD155 complexed with poliovirus have been obtained using electron microscopy while a high resolution structures of theectodomain D1 and D2 of CD155 were solved by x-ray crystallography.
프론티어 진행
의약품 개발 진행- 영어 이름：
Poliovirus receptor
- 카테고리：
- 상장 의약품 수：
0 상세
- 임상 의약품 수：
2 상세
- 최고 개발 단계：
Phase 2 Clinical
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
